Law360 (February 16, 2021, 9:44 PM EST) — South Korean-based Daewoong Pharmaceuticals can keep its low-cost version of Allergan’s Botox treatment on the market while the Federal Circuit considers whether it should pause the U.S. International Trade Commission’s import ban that was set to begin this week.
In an order Monday, the Federal Circuit granted Daewoong’s request to temporarily halt the ITC’s ban blocking the Korean drugmaker from importing its product Jeveau into the U.S. “until further notice while the court considers the motion for a stay pending appeal.”
The ITC in December found that Daewoong and its U.S. licensee Evolus Inc. misappropriated manufacturing trade secrets belonging to Allergan’s…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!